Five Prime Therapeutics (FPRX) Tops Q2 EPS by 30c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q2 EPS of ($0.99), $0.30 better than the analyst estimate of ($1.29). Revenue for the quarter came in at $7.58 million versus the consensus estimate of $10.34 million.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15